Bolt Bio Reiterates Going Concern Warning as Cash Drops to $18.1M — Runway Only Into Q1 2027
BOLT is trading near its 52-week low of $3.75 (6.1% above the low) on light trading volume (0.2× avg).
Summary
Bolt Biotherapeutics' Q2 2026 10-Q shows cash and investments of $18.1 million, down from $23.9 million at Q1, with management warning the company may not survive beyond Q1 2027 without new funding.
Updates
· Reuters — Q2 net loss was $7.72 million, with collaboration revenue of $5,000. BDC-4182 Phase 1/2 trial advanced to Cohort 4, with initial data expected in Q3 2026.
Key Events · Earnings and Guidance · BOLT
-
Going Concern Warning Reiterated
Management states cash and investments of $18.1 million as of June 30, 2026 will not be sufficient to continue as a going concern for at least one year, with runway only into Q1 2027.
-
Cash Burn Accelerates
Cash and investments declined from $23.9 million at March 31, 2026 to $18.1 million at June 30, 2026, a $5.8 million drop in one quarter.
-
Collaboration Revenue Collapses
Collaboration revenue fell to just $31,000 in H1 2026 from $3.0 million in H1 2025, as both the Genmab and Toray partnerships are effectively paused pending clinical data.
-
Impairment Charge from Sublease Termination
A $0.8 million impairment charge was taken on right-of-use assets after a subtenant exercised its right to terminate, adding to the financial strain.
Analysis · BOLT · Life Sciences
Bolt Biotherapeutics' Q2 2026 filing confirms the company is running out of money. Cash and investments fell to $18.1 million from $23.9 million just three months ago, and management explicitly states this is not enough to fund operations for a full year. The company now projects its cash will last only into the first quarter of 2027. With collaboration revenue from Genmab and Toray essentially dried up and a $0.8 million impairment charge from a sublease termination, the financial picture has deteriorated sharply. The going concern warning is no longer theoretical — it is an immediate survival question.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BOLT was trading at $3.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.6M. The 52-week trading range was $3.75 to $7.20. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.